about
Pharmacogenomics discovery and implementation in genome-wide association studies eraEffects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysisEffect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarinEffect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysisVKORC1 pharmacogenetics and pharmacoproteomics in patients on warfarin anticoagulant therapy: transthyretin precursor as a potential biomarkerConcomitant use of prescription medications and dietary supplements in menopausal women: an approach to provider preparedness.Warfarin anticoagulant therapy: a Southern Italy pharmacogenetics-based dosing model.Suppression of statin effectiveness by copper and zinc in yeast and human cellsFunctional study of the vitamin K cycle in mammalian cells.The impact of VKORC1-1639 G>A polymorphism on the maintenance dose of oral anticoagulants for thromboembolic prophylaxis in North India: A pilot studySurvey of US public attitudes toward pharmacogenetic testing.Warfarin toxicity and individual variability-clinical case.Warfarin glycosylation invokes a switch from anticoagulant to anticancer activity.Human vitamin K epoxide reductase and its bacterial homologue have different membrane topologies and reaction mechanismsTransitions of care in anticoagulated patients.A population-based assessment of the drug interaction between levothyroxine and warfarinClinical applications of pharmacogenomics guided warfarin dosing.Structural and functional insights into human vitamin K epoxide reductase and vitamin K epoxide reductase-like1.Novel oral anticoagulants: pharmacology, coagulation measures, and considerations for reversal.Pharmacogenetic aspects of coumarinic oral anticoagulant therapies.Next generation sequencing: implications in personalized medicine and pharmacogenomics.Impact of Body Mass Index and Genetics on Warfarin Major Bleeding Outcomes in a Community Setting.Influence of CYP2C9 polymorphism on the fall in International Normalized Ratio in patients interrupting warfarin therapy before elective surgery.Learning from product labels and label changes: how to build pharmacogenomics into drug-development programs.Personalized medicine: a patient-centered paradigm.The population attributable fraction as a measure of the impact of warfarin pharmacogenetic testing.A genetic marker at the OLIG3/TNFAIP3 locus associates with methotrexate continuation in early inflammatory polyarthritis: results from the Norfolk Arthritis Register.Pharmacogenetics in cardiovascular disease: the challenge of moving from promise to realization: concepts discussed at the Canadian Network and Centre for Trials Internationally Network Conference (CANNeCTIN), June 2009.Assessment of the efficacy of a novel tailored vitamin K dosing regimen in lowering the International Normalised Ratio in over-anticoagulated patients: a randomised clinical trial.Association between CYP4F2 genotype and circulating plasma vitamin K concentration in children on chronic warfarin therapy: Possible long-term implications for bone development and vascular health.High intra- and inter-individual variability of plasma vitamin K concentrations in patients with atrial fibrillation under warfarin therapy.Influence of VKORC1 gene polymorphisms on the effect of oral vitamin K supplementation in over-anticoagulated patients.A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy.An evaluation of the potential drug interaction between warfarin and levothyroxine.Bridging the efficacy–effectiveness gap: a regulator's perspective on addressing variability of drug responsePharmacogenetics of Adverse Drug Reactions
P2860
Q27001573-FE4E08D6-BF6E-44FB-B6B3-7D341C417836Q27026134-72D58CCE-57FA-4159-B961-4424E8E19720Q28276514-170A41CF-2A59-47EE-B461-D26110529FF9Q28276605-91039556-9C76-4A50-97DF-CB0A74848C71Q28476502-109C093E-F3B1-4F76-8604-8566516AFF37Q30226808-1E0BC22B-E432-45D8-B119-9A8495889212Q31131437-2408CCDC-D170-4659-89CC-C64E29D0B893Q33750330-E02A5D1B-D305-465B-9A7C-E1EDF07A2C2CQ34707195-4AFFC771-DE66-43FF-B2E5-EC4493EC4298Q35073505-B13C4B4E-B3F3-404E-9F45-82966AF1B567Q35115860-FDB32A5E-AAC6-4DFB-B913-0EB38426208CQ35155651-7681D2CC-AE30-4ED1-B094-EE8C225C62F7Q35552971-0D9A1979-1047-43B8-BF7D-59B407969304Q36298281-E900E743-4211-4088-98B5-25F1F13D1CF5Q36957947-41D7BE3E-01E5-47A2-A598-F13E096C2693Q37014216-79892AA3-FBB1-41AA-8C36-D07FFD1EA919Q37807280-937F7268-5210-4892-B185-2BA42ABEACC4Q38103055-993ED9A2-8EFB-428E-9EE4-AA4BFD281BCAQ38127582-D11FFB87-ADEC-4511-B688-EEBADC189CE4Q38266460-182AF9B3-AC69-45E4-B00A-D3ADF07D7405Q38804924-9FDD5BFC-B608-4B23-A2C6-11D6A34DA6FCQ38824447-6237750C-E523-403D-BC26-3F4A920E3255Q40903055-416A0177-5B02-4E81-AEA7-74A69517B404Q42782253-D05D612B-80D7-499F-A304-B6286DF6CEBEQ43057310-708CABA1-60C4-4306-A77E-8A618055C897Q44498037-B26842B5-8D21-4CDE-AB9D-66208AC0FA70Q45252920-FA6DB76B-02D0-4719-9FB2-D1E52FA6F8DCQ45337198-6897A93D-34C5-4DDD-AF7C-E155EF1EFB15Q47740885-B0E1DAD9-BFC5-4545-9207-327331AF4815Q47840101-A43EEFD4-FD3D-47D0-871E-7BBC3D455581Q49124249-95058739-4431-4770-BA78-5D9B38FFF68BQ50903331-C3A12731-21E3-491B-9A05-9CD9870410BAQ51514655-ACB481AA-23A0-4025-843E-A7468024EA41Q53088730-20EF0E92-7D95-4F19-89E5-7EFE7A7CB472Q56828560-D147373E-B369-4C18-83A0-2C9E118EB0DBQ57302675-53B75010-6B74-4F64-9E8D-92280C66F466
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacogenetics of warfarin.
@en
Pharmacogenetics of warfarin.
@nl
type
label
Pharmacogenetics of warfarin.
@en
Pharmacogenetics of warfarin.
@nl
prefLabel
Pharmacogenetics of warfarin.
@en
Pharmacogenetics of warfarin.
@nl
P1476
Pharmacogenetics of warfarin.
@en
P2093
Farhad Kamali
Hilary Wynne
P356
10.1146/ANNUREV.MED.070808.170037
P577
2010-01-01T00:00:00Z